Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients
Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients
复制标题
DOI：
10.1016/j.ejca.2006.03.033
复制
发表时间：
2006-10-01
影响因子：
8.4
通讯作者：
Regateiro, Fernando J.
中科院分区：
文献类型：
--
作者：
Silva, Henriqueta A. C.;Abraul, Elsa;Regateiro, Fernando J.
本研究的目的是评估表皮生长因子受体变体III，EGFRvIII，一种癌症特异性突变体，作为诊断乳腺癌隐匿性系统性疾病的可能标志物。通过RT-nested PCR以高灵敏度鉴定EGFRvIII mRNA。在研究的102名女性中，在33名低风险早期患者的外周血中检测到突变体，在18名选择进行新辅助化疗的患者中检测到突变体的比例为56%，在11名播散性疾病患者中检测到突变体的比例为63.6%，在40名对照女性中检测到突变体的比例为0%。在低风险的早期患者中，存在一种或多种预测复发的肿瘤特征，如缺乏雌激素受体和存在ERBB 2或组织学分级G2/G3，与EFGR vIII检测显著相关（p < 0.05）。EGFRvIII mRNA具有作为诊断乳腺癌中隐匿性系统性疾病的有用标志物的特性。后续研究将评估其作为全身治疗决策标准的临床价值。(c)2006爱思唯尔有限公司保留所有权利。
The aim of this study is to evaluate epidermal growth factor receptor variant III, EGFRvIII, a cancer specific mutant, as a possible marker for the diagnosis of breast cancer occult systemic disease. EGFRvIII mRNA was identified by an RT-nested PCR with a high sensitivity. In 102 women studied, the mutant was detected in the peripheral blood of 30% of 33 low risk, early stage patients, in 56% of 18 patients selected for neoadjuvant chemotherapy, in 63.6% of 11 patients with disseminated disease and 0% of 40 control women. in low risk, early stage patients, the presence of one or more tumour characteristics predicting recurrence such as the absence of oestrogen receptors and the presence of ERBB2 or histologic grades G2/G3 was significantly associated with EFGRvIII detection (p < 0.05). EGFRvIII mRNA has characteristics to be a useful marker for the diagnosis of occult systemic disease in breast cancer. Follow-up studies will evaluate its clinical value as a decision criterion for systemic therapy. (c) 2006 Elsevier Ltd. All rights reserved.